Ascendis Pharma AS (ASND NASDAQ) stock market data APIs
$249.8772
2.18(0.9%)
as of November 2, 2026
Try our APIs with
free plan!
Ascendis Pharma AS Financial Data Overview
Price chart is built with
Anychart
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Prev. Close
249.8772
Open
252.053
High
255.7218
Low
248.3687
52 wk Range
188.0711-282.15
Market Cap
16 534 M
P/E Ratio
19.2544
Shares Outstanding
65 804 K
Revenue
1 047 M
EPS
3.29
Beta
0.485
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ascendis Pharma AS (top by weight)
Ticker
100-day Price Change
Weight
W311.XETRA
HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Accumulating
0.47
(6.51%)
8.98
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ascendis Pharma AS data using free add-ons & libraries
Get Ascendis Pharma AS Fundamental Data
Ascendis Pharma AS Fundamental data includes:
- Net Revenue: 1 047 M
- EBITDA: 263 M
- Earnings Per Share: 13
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: 0.78
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ascendis Pharma AS News
New
Eyconis to Participate in Upcoming Investor Conferences
Eyconis Inc. REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announ...
Hasbro Upgraded, General Motors Downgraded: Updated Rankings on Top Blue-Chip Stocks
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutiona...
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
Ascendis Pharma, LLC COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful impro...
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market
REX Shares recently launched the REX Peptide ETF (PEPT), a thematic fund offering global exposure to the peptide industry, from drug developers to manufacturers and delivery platforms. Inside PEPT ET...
Get Ascendis Pharma AS fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.